GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis.

Accelerated glycolysis is one of the biochemical characteristics of cancer cells. The glucose transporter isoform 1 (GLUT1) gene encodes a key rate-limiting factor in glucose transport into cancer cells. However, its expression level and functional significance in hepatocellular cancer (HCC) are still disputed. Therefore, we aimed to analyze the expression and function of the GLUT1 gene in cases of HCC. We found significantly higher GLUT1 mRNA expression levels in HCC tissues and cell lines compared with primary human hepatocytes and matched nontumor tissue. Immunohistochemical analysis of a tissue microarray of 152 HCC cases revealed a significant correlation between Glut1 protein expression levels and a higher Ki-67 labeling index, advanced tumor stages, and poor differentiation. Accordingly, suppression of GLUT1 expression by siRNA significantly impaired both the growth and migratory potential of HCC cells. Furthermore, inhibition of GLUT1 expression reduced both glucose uptake and lactate secretion. Hypoxic conditions further increased GLUT1 expression levels in HCC cells, and this induction was dependent on the activation of the transcription factor hypoxia-inducible factor-1alpha. In summary, our findings suggest that increased GLUT1 expression levels in HCC cells functionally affect tumorigenicity, and thus, we propose GLUT1 as an innovative therapeutic target for this highly aggressive tumor.

[1]  F. Haller,et al.  Altered regulation of Prox1-gene-expression in liver tumors , 2008, BMC Cancer.

[2]  R. Airley,et al.  Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies , 2008, Cancer Chemotherapy and Pharmacology.

[3]  A. Bosserhoff,et al.  The novel gene MIA2 acts as a tumour suppressor in hepatocellular carcinoma , 2007, Gut.

[4]  A. Mobasheri,et al.  Hypoxic Regulation of Glucose Transport, Anaerobic Metabolism and Angiogenesis in Cancer: Novel Pathways and Targets for Anticancer Therapeutics , 2007, Chemotherapy.

[5]  J. Pouysségur,et al.  Hypoxia signalling controls metabolic demand. , 2007, Current opinion in cell biology.

[6]  Y. Tokusashi,et al.  Hypoxia-independent overexpression of hypoxia-inducible factor 1alpha as an early change in mouse hepatocarcinogenesis. , 2006, Cancer research.

[7]  Chi V Dang,et al.  Cancer's molecular sweet tooth and the Warburg effect. , 2006, Cancer research.

[8]  Ronald A. DePinho,et al.  Hepatocellular carcinoma pathogenesis: from genes to environment , 2006, Nature Reviews Cancer.

[9]  A. Bosserhoff,et al.  Raf kinase inhibitor protein is downregulated in hepatocellular carcinoma. , 2006, Oncology reports.

[10]  H. Pelicano,et al.  Glycolysis inhibition for anticancer treatment , 2006, Oncogene.

[11]  A. Bosserhoff,et al.  Promoter-hypermethylation is causing functional relevant downregulation of methylthioadenosine phosphorylase (MTAP) expression in hepatocellular carcinoma. , 2006, Carcinogenesis.

[12]  A. Monks,et al.  Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. , 2005, Cancer research.

[13]  A. Bosserhoff,et al.  In situ expression patterns of melanoma inhibitory activity 2 in healthy and diseased livers , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[14]  Geng-Wen Huang,et al.  Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in hepatocellular carcinoma: Impact on neovascularization and survival. , 2005 .

[15]  G. Gores,et al.  Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. , 2005, Journal of hepatology.

[16]  G. Cheon,et al.  [Positron emission tomography with fluorine-18-fluorodeoxyglucose is useful for predicting the prognosis of patients with hepatocellular carcinoma]. , 2004, The Korean journal of hepatology.

[17]  J. Vera,et al.  Predicting the three-dimensional structure of the human facilitative glucose transporter glut1 by a novel evolutionary homology strategy: insights on the molecular mechanism of substrate migration, and binding sites for glucose and inhibitory molecules. , 2004, Biophysical journal.

[18]  H. El‐Serag,et al.  Hepatocellular carcinoma: recent trends in the United States. , 2004, Gastroenterology.

[19]  M. Roh,et al.  Diagnostic utility of GLUT1 in the differential diagnosis of liver carcinomas. , 2004, Hepato-gastroenterology.

[20]  S. Fan,et al.  The Potential Role of Hypoxia Inducible Factor 1α in Tumor Progression after Hypoxia and Chemotherapy in Hepatocellular Carcinoma , 2004, Cancer Research.

[21]  N S Thakker,et al.  Prognostic value of facilitative glucose transporter Glut-1 in oral squamous cell carcinomas treated by surgical resection; results of EORTC Translational Research Fund studies. , 2004, European journal of cancer.

[22]  J. Bruix,et al.  Focus on hepatocellular carcinoma. , 2004, Cancer cell.

[23]  R. Airley,et al.  Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma? , 2003, British Journal of Cancer.

[24]  Jinho Kim,et al.  YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. , 2003, Journal of the National Cancer Institute.

[25]  W. Thasler,et al.  Collagen sandwich culture affects intracellular polyamine levels of human hepatocytes , 2002, Cell proliferation.

[26]  F. Fogt,et al.  Assessment of Glut-1 expression in cholangiocarcinoma, benign biliary lesions and hepatocellular carcinoma. , 2002, Oncology reports.

[27]  M. Bibbo,et al.  Diagnostic utility of Glut‐1 and CA 15‐3 in discriminating adenocarcinoma from hepatocellular carcinoma in liver tumors biopsied by fine‐needle aspiration , 2002, Cancer.

[28]  G. Owen,et al.  Glucose transporters: expression, regulation and cancer. , 2002, Biological research.

[29]  C. Teng,et al.  Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. , 2001, Biochemical pharmacology.

[30]  M. Laeeq Khan,et al.  Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. , 2000, Journal of hepatology.

[31]  M. Raizada,et al.  Regulation of brain glucose transporters by glucose and oxygen deprivation. , 1999, Metabolism: clinical and experimental.

[32]  M. Younes,et al.  Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. , 1996, Cancer research.

[33]  L. Levitsky,et al.  Glucose regulation of glucose transporters in cultured adult and fetal hepatocytes. , 1995, Metabolism: clinical and experimental.

[34]  L. Levitsky,et al.  GLUT-1 and GLUT-2 mRNA, protein, and glucose transporter activity in cultured fetal and adult hepatocytes. , 1994, The American journal of physiology.

[35]  R. Grobholz,et al.  Reduction in the expression of glucose transporter protein GLUT 2 in preneoplastic and neoplastic hepatic lesions and reexpression of GLUT 1 in late stages of hepatocarcinogenesis. , 1993, Cancer research.

[36]  R. Viebahn,et al.  Differences in glycolytic capacity and hypoxia tolerance between hepatoma cells and hepatocytes , 1991, Hepatology.

[37]  Kazutomo Inoue,et al.  Over-expression of facilitative glucose transporter genes in human cancer. , 1990, Biochemical and biophysical research communications.

[38]  C. Chi,et al.  Elevation of facilitated glucose‐transporter messenger RNA in human hepatocellular carcinoma , 1990, Hepatology.